CDK4 and breast carcinoma: A network meta-analysis showed that the combinations of CDK4/6 inhibitors, such as PAL, ribociclib, and abemaciclib, with high-dose FUL were among the most effective treatment options for advanced ER+ breast cancer as reflected in overall and progression-free survival [38].